Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
Chris von Heymann, BSc Phm
Advertisement
Articles by Chris von Heymann, BSc Phm
Advertisement
Latest Updated Articles
- Private-payer Costs for Employees with Treatment-resistant Depression
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
3
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
4
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
5
